323 related articles for article (PubMed ID: 25213317)
1. Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective.
Seguí MÁ; Crespo C; Cortés J; Lluch A; Brosa M; Becerra V; Chiavenna SM; Gracia A
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):889-99. PubMed ID: 25213317
[TBL] [Abstract][Full Text] [Related]
2. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
[TBL] [Abstract][Full Text] [Related]
3. Economic Impact of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in France.
Katz G; Romano O; Foa C; Vataire AL; Chantelard JV; Hervé R; Barletta H; Durieux A; Martin JP; Salmon R
PLoS One; 2015; 10(6):e0128880. PubMed ID: 26086912
[TBL] [Abstract][Full Text] [Related]
4. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization.
Klang SH; Hammerman A; Liebermann N; Efrat N; Doberne J; Hornberger J
Value Health; 2010; 13(4):381-7. PubMed ID: 20412544
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer.
Paulden M; Franek J; Pham B; Bedard PL; Trudeau M; Krahn M
Value Health; 2013; 16(5):729-39. PubMed ID: 23947965
[TBL] [Abstract][Full Text] [Related]
6. Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies.
Blank PR; Schwenkglenks M; Moch H; Szucs TD
Breast Cancer Res Treat; 2010 Nov; 124(2):497-507. PubMed ID: 20364309
[TBL] [Abstract][Full Text] [Related]
7. A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.
Li Y; Arellano AR; Bare LA; Bender RA; Strom CM; Devlin JJ
Value Health; 2017 Apr; 20(4):547-555. PubMed ID: 28407996
[TBL] [Abstract][Full Text] [Related]
8. Long-term cost-effectiveness of Oncotype DX® versus current clinical practice from a Dutch cost perspective.
Kip M; Monteban H; Steuten L
J Comp Eff Res; 2015 Sep; 4(5):433-45. PubMed ID: 25872415
[TBL] [Abstract][Full Text] [Related]
9. Prospective cost-effectiveness analysis of genomic profiling in breast cancer.
Retèl VP; Joore MA; Drukker CA; Bueno-de-Mesquita JM; Knauer M; van Tinteren H; Linn SC; van Harten WH
Eur J Cancer; 2013 Dec; 49(18):3773-9. PubMed ID: 23992641
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of 70-gene MammaPrint signature in node-negative breast cancer.
Chen E; Tong KB; Malin JL
Am J Manag Care; 2010 Dec; 16(12):e333-42. PubMed ID: 21291290
[TBL] [Abstract][Full Text] [Related]
11. Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer.
Cosler LE; Lyman GH
Cancer Invest; 2009 Dec; 27(10):953-9. PubMed ID: 19909009
[No Abstract] [Full Text] [Related]
12. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.
Yang M; Rajan S; Issa AM
Cancer; 2012 Oct; 118(20):5163-70. PubMed ID: 22359236
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer.
Hall PS; McCabe C; Stein RC; Cameron D
J Natl Cancer Inst; 2012 Jan; 104(1):56-66. PubMed ID: 22138097
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer.
Retèl VP; Joore MA; Knauer M; Linn SC; Hauptmann M; Harten WH
Eur J Cancer; 2010 May; 46(8):1382-91. PubMed ID: 20359886
[TBL] [Abstract][Full Text] [Related]
16. Population-Based Study to Determine the Health System Costs of Using the 21-Gene Assay.
Mittmann N; Earle CC; Cheng SY; Julian JA; Rahman F; Seung SJ; Levine MN
J Clin Oncol; 2018 Jan; 36(3):238-243. PubMed ID: 29193984
[TBL] [Abstract][Full Text] [Related]
17. Budget impact analysis of gene expression tests to aid therapy decisions for breast cancer patients in Germany.
Lux MP; Nabieva N; Hildebrandt T; Rebscher H; Kümmel S; Blohmer JU; Schrauder MG
Breast; 2018 Feb; 37():89-98. PubMed ID: 29128582
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Sofrygin O; Thomas SK; Papo NL; Barghout V
Clin Breast Cancer; 2007 Jun; 7(8):608-18. PubMed ID: 17592673
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of molecular profiling for adjuvant decision making in patients with node-negative breast cancer.
Bonastre J; Marguet S; Lueza B; Michiels S; Delaloge S; Saghatchian M
J Clin Oncol; 2014 Nov; 32(31):3513-9. PubMed ID: 25287824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]